How Should Microbiota-directed Foods Be Regulated?

July 13, 2017

The Global Health Center, headed by William Powderly, MD, is working with the Center for Gut Microbiome and Nutrition Research, directed by Jeffrey Gordon, MD, and a multidisciplinary team of Washington University faculty, staff, and trainees in a gut microbiome initiative designed to address a range of scientific, regulatory, ethical, social, cultural, and policy considerations that underpin the development of next generation nutribiotics for childhood undernutrition.

Scholars
William G. Powderly headshot
Larry J. Shapiro Director, Institute for Public Health; J. William Campbell Professor of Medicine and Co-Director of the Division of Infectious Diseases, School of Medicine
Projects

There is rapid growth in the number of products that claim to affect the gut microbiota and benefit health. (Illustration: V. Altounian/Science)

Team members Jonathan M. Green, MD, MBA, Associate Director of the Global Health Center; Michael J. Barratt, PhD, Executive Director of the Center for Gut Microbiome and Nutrition Research; Michael Kinch, PhD, Associate Vice Chancellor and Director at the Center for Research Innovation in Business; and Jeffrey I. Gordon, MD, the Dr. Robert J. Glaser Distinguished University Professor, are all authors on a paper recently published in Science discussing how microbiota-directed food might fit within the current Food and Drug Administration (FDA) regulatory framework. 

Scholars
Professor, School of Medicine and Associate Dean of Human Studies
Associate Vice Chancellor and Director, Center for Research Innovation in Business, and Professor of Radiation Oncology, School of Medicine

Research continues to show that gut microbiota is an important determinant of healthy growth and of our metabolic, physiologic, immune, and perhaps neurologic phenotypes, thus it is a logical target for intervention. Microbiota directed foods (MDFs) are designed to specifically alter the structure or function of the gut microbiome, with the goal of improving a person’s health.  The development and use of MDFs as either a preventative or therapeutic approach raises the question as to how MDFs should be regulated. This will affect innovation incentives, product quality, consumer access, and public health. Given that the regulations predate our recognition of the key role of the microbiome in health and disease, it is perhaps not surprising that MDFs do not fit cleanly into the existing regulatory paradigm.

The U.S. FDA regulations provide for a number of distinct categories under which an MDF might be classified, such as a conventional food, medical food, dietary supplement or even as a drug. Each has specific criteria, and the classification determines what sort of health claims can be made and the level of evidence required to support such a claim. For example, a claim that an MDF can prevent the development of diabetes might result in the MDF being classified as a drug. In contrast, a claim that the MDF promotes a healthy metabolism might be allowable for a conventional food or dietary supplement.  While this may seem a somewhat esoteric concern, it will have a profound impact on the costs of development and subsequent availability of an MDF.

Dr. Green believes that MDFs should be subject to the minimum regulatory burden consistent with safe use of the product. Given the potential profound impact that these may have on a number of diseases, including the global problem of undernutrition, over-regulation may adversely affect the development of a safe and effective treatment.

Read the full article published in the July 7, 2017 issue of Science.